{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:36:41Z","timestamp":1747183001360,"version":"3.40.5"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["2019GSF108105"],"award-info":[{"award-number":["2019GSF108105"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["11971269"],"award-info":[{"award-number":["11971269"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The optimal microparticle size for drug\u2010eluting beads transarterial chemoembolization (DEB\u2010TACE) remains unknown. This retrospective cohort study analyzed the efficacy and safety of CalliSpheres microsphere embolization in the treatment of unresectable hepatocellular carcinoma (HCC) to determine the influence of particle size on the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Forty\u2010two patients with unresectable HCC were enrolled in this retrospective study from January 2018 to January 2020. Patients received DEB\u2010TACE with CalliSpheres of 100\u2013300 \u03bcm (small\u2010size, <jats:italic>n<\/jats:italic>\u00a0=\u00a015) or 300\u2013500 \u03bcm (medium\u2010size, <jats:italic>n<\/jats:italic>\u00a0=\u00a027). The tumor response was evaluated via enhanced CT or MRI at 1 month, 3 months, and 6 months after treatment, based on the Modified Response Evaluation Criteria in Solid Tumors. Adverse events after DEB\u2010TACE were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Complete response, partial response, stable disease, and progressive disease were recorded in 20%, 20%, 33.3%, 26.7%, respectively, of patients in the small\u2010size group and 3.7%, 25.9%, 44.4%, 25.9% of patients in the medium\u2010size group, respectively. No significant difference was found between the two groups (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.516). Major adverse events, including grade three liver toxicity (<jats:italic>n<\/jats:italic>\u00a0=\u00a04) and liver abscess (<jats:italic>n<\/jats:italic>\u00a0=\u00a03), occurred significantly more in the small\u2010size group, while none were reported in the medium size group (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>DEB\u2010TACE with medium\u2010size (300\u2013500 \u03bcm) CalliSpheres microspheres had similar efficacy and a better safety profile than DEB\u2010TACE with small\u2010size (100\u2013300 \u03bcm) CalliSpheres, indicating that medium\u2010size microspheres may be a better choice for unresectable primary liver cancer.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13660","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T06:09:58Z","timestamp":1635401398000},"page":"388-393","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Drug\u2010eluting bead transarterial chemoembolization with medium\u2010sized versus small\u2010sized CalliSpheres microspheres in unresectable primary liver cancer"],"prefix":"10.1111","volume":"18","author":[{"given":"Jiao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Health Gastroenterology Shandong Provincial Hospital Affiliated to Shandong First Medical University  Jinan Shandong China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo\u2010an","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery Juye County People\u2019 Hospital  Heze Shandong Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Interventional Medicine The Second Hospital Cheeloo College of Medicine Shandong University Interventional Oncology Institute of Shandong University  Jinan Shandong Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9431-7153","authenticated-orcid":false,"given":"Wujie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Interventional Medicine The Second Hospital Cheeloo College of Medicine Shandong University Interventional Oncology Institute of Shandong University  Jinan Shandong Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7753"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20933"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1333648"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2241011262"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i2.161"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2012.11.023"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2014.12.020"},{"key":"e_1_2_9_11_1","first-page":"242","article-title":"The targeting of drugs parenterally by use of microspheres","volume":"36","author":"Illum L","year":"1982","journal-title":"J Parenter Sci Technol"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(98)00047-2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1051-0443(07)60429-1"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-012-0424-y"},{"key":"e_1_2_9_15_1","first-page":"372","article-title":"The ten commandments of chemoembolization: expert discussion and report from Mediterranean interventional oncology (MIOLive) congress 2017","volume":"22","author":"Malagari K","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy510"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50047"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33156"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02221.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040791"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100208"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227475"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2016.05.013"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-013-0777-x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.108966"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.RVI.0000228416.21560.7F"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.13.12308"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.5152\/dir.2019.19261"},{"key":"e_1_2_9_29_1","first-page":"549","article-title":"[Development of CalliSpheres\u00ae embolic microspheres]","volume":"24","author":"Guan YS","year":"2016","journal-title":"Chinese J Hepatol"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61209-6"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13660","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13660","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:54:39Z","timestamp":1692838479000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/ajco.13660"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13660","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"type":"print","value":"1743-7555"},{"type":"electronic","value":"1743-7563"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"2021-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}